## **AETNA BETTER HEALTH® OF VIRGINIA REQUEST FORM**

## Antimigraine Agents, Others

Fax back to: 1-855-799-2553

If the following information is not complete, correct, or legible, the PA process can be delayed. Please use one form per member.

MEMBER INFORMATION														
Last Name: First	: Name:													
Medicaid ID Number: Date	Date of Birth:													
Weight in Kilograms:														
PRESCRIBER INFORMATION														
Last Name: First	First Name:													
NPI Number:														
Phone Number: Fax	Number:													
DRUG INFORMATION														
Drug Name/Form:														
Strength:														
Dosing Frequency:														
Length of Therapy:														
Quantity per Day:														
Preventive treatmen	t of migraine													
Preferred Agents *step edit required	Non-Preferred Agents (PA required)													
Aimovig®, Ajovy® and Ajovy® autoinjector	Emgality® syringe (100 mg), Vyepti®													
Emgality® pen and syringe (120 mg), Nurtec® ODT,														
Qulipta™ Acute treetment of	f migraina													
Acute treatment of 2 gaparis triptons														
Preferred Agents (No PA with trial of 2 generic triptans)  Nurtec® ODT, Ubrelvy™	Non-Preferred Agents (PA required)  Reyvow®, Trudhesa™, Zavzpret™													
ivalued ODI, Oblewy	neyvow, indunesa, zavzpiet													

(Form continued on next page.)

C16485-C 04-2024 Revised: 03/21/2024 | Effective: 07/01/2024 Page 1 of 4

AETNA BETTER HEALTH® OF VIRGINIA REQUEST FORM: Antimigraine Agents, Others

Member's Last Name:												Member's First Name:												
DF	DRUG INFORMATION (Continued)																							
Ide	entify	why	the pr	eferr	ed a	gent	s can	not	be u	ised.														
DI	AGN(	OSIS	AND I	MED	ICAL	INF	ORIV	1ATI	ON															
All	drug	s in t	his cla	ss are	e elig	ible	to re	ceiv	e a S	SIX (6	)-m	onth	1 арр	rova	al. Co	mpl	ete t	he fo	llow	ing q	uest	ions.		
Fo	r Prev	entiv/	ve trea	tmer	nt of	migr	raine	, do	es th	e me	mk	er m	eet	the *	step	edit	ANI	) the	follo	wing	g crit	eria?	)	
1.	of H		memb che Dis			_			_					out a	ura b	ased	d on I	nteri	natio	nal C	:lassi	ficati	on	
_						r	_																	
2.	Is th	e me	mber ≥	: 18 y	ears)	of a	ge!	AND	)															
	Y	es/	∐ N	lo																				
3.	Has	the n	nembe	r had	1 ≥ 4	migr	aine	days	s per	mon	th	for a	t leas	st 3 n	nont	hs? 🖊	AND							
	Y	es/		lo																				
4.	*Has	s the	memb	er tri	ied a	nd fa	iled	a ≥ 1	l mo	nth tı	rial	of ar	ny 2 (	of the	e foll	owir	ng ora	al gei	neric	med	licatio	ons?		
	• E	Beta l Anti-e	epress plocker pilept tensin	rs (e.¿ ics (e	g., pi .g., v	opra alpro	nolo pate,	l, me topi	etop iram	rolol, ate)	tin	nolol				blocl	kers (	(e.g.,	lisine	opril,	, canı	desar	tan)	
		Yes		lo																				
5.	For N	Nurte	c and	Qulip	ta, h	as th	ne me	emb	er tri	ied aı	nd 1	failed	1 1 of	fthe	pref	erred	d inje	ctab	le ag	ents	?			
	Y	es/	N	lo																				
Fo	r rene	ewal,	compl	ete t	he f	ollow	ing o	ques	tion	to re	cei	ive a	TWE	LVE	(12)-	mon	th a	prov	val.					
1.	Did t	the m	embe	r den	nons	trate	sign	ifica	nt de	ecrea	se i	in the	e nur	nber	, fred	quen	су, о	r inte	ensity	y of h	neada	aches	?	
	Y	es/		lo																				
(Fc	orm co	ontin	ued on	next	pag	e.)																		

C16485-C 04-2024 Revised: 03/21/2024 | Effective: 07/01/2024 Page 2 of 4

## AETNA BETTER HEALTH® OF VIRGINIA REQUEST FORM: Antimigraine Agents, Others

Member's Last Name:													Member's First Name:											
Foi	or Acute treatment of migraine, does the member meet the *step edit AND the following criteria?																							
1.	Does the member have a diagnosis of migraine with or without aura? AND																							
	☐ Yes ☐ No																							
2.	. Is the member ≥ 18 years of age? <b>AND</b>																							
	☐ Yes ☐ No																							
3.	*Has the member tried and failed (or has contraindications to) two preferred triptan medications?																							
	Yes No																							
4.	Prior	to i	nitiat	ion	of Tr	udhe	esa™	, a c	ardic	vasc	cular	ev	aluat	ion i	s rec	omn	nend	ed. F	las tl	nis be	een d	comp	letec	?k
	Y	es		] No																				
Foi	rene	wal,	com	plet	e th	e fol	lowi	ng q	uest	ion t	o re	ceiv	ve a	TWE	LVE (	(12)-	mon	th ap	prov	al.				
2.	Did t	he n	nemb	oer d	emo	nstr	ate s	ignif	ican	t dec	reas	e i	n the	nun	nber,	freq	uend	cy, oı	rinte	nsity	of h	eada	ches	;?
	Y	es		] No																				
(Fo	rm co	ntin	ued (	on ne	ext p	age.	)																	

C16485-C 04-2024 Revised: 03/21/2024 | Effective: 07/01/2024 Page 3 of 4

	Member's Last Name:													Member's First Name:												
Foi	or Episodic Cluster Headache, does the member meet the following criteria?																									
1.	Does the member have a diagnosis of episodic cluster headache? <b>AND</b>																									
	Yes No Is the member ≥ 18 years of age? AND																									
2.	Is the	e me	mber	≥ 18 y	ears	of ag	e? <b>A</b>	ND																		
	Yes No																									
3.	Has the member experienced at least 2 cluster periods lasting from 7 days to 365 days, separated by pain-free periods lasting at least three months? AND														ain-											
	☐ Yes ☐ No																									
4.	<ul> <li>Medication will not be used in combination with another CGRP antagonist or inhibitor used for the preventive treatment of migraines? AND</li> </ul>																									
	☐ Yes ☐ No																									
5.	. Has the member tried and failed (or has contraindications to) at least one standard prophylactic (preventive) pharmacologic therapy for cluster headache?																									
	Y	es		No																						
Foi	rene	wal,	comp	lete t	he fo	llowi	ng q	uest	ion t	o re	ceiv	ve a	TWE	LVE (	12)-ı	nont	th ap	prov	al.							
1.	Did t	he n	nembe	er den	nonst	rate	signif	fican	t ded	reas	e i	n the	nun	nber,	freq	uend	cy, or	inte	nsity	of h	eada	ches	?			
	Y	es		No																						
Pro	escrib	er Si	gnatu	re (Re	quire	ed)											Da	te								
Ву	signa	ture,	the p	hysici	an co	nfirm	ns the	e ab	ove i	nfor	ma	tion	is acc	curat	e an	d ver	ifiab	le by	mer	nber	reco	rds.				
	Please include ALL requested information; Incomplete forms will delay the PA process.																									

C16485-C 04-2024 Revised: 03/21/2024 | Effective: 07/01/2024 Page 4 of 4